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Abstract
Background: The USDA, Wildlife Services cooperative oral rabies vaccination (ORV) program
uses a live vaccinia virus-vectored (genus Orthopoxvirus) vaccine, Raboral V-RG® (V-RG), to
vaccinate specific wildlife species against rabies virus in several regions of the U.S. Several naturally
occurring orthopoxviruses have been found in North America, including one isolated from
asymptomatic raccoons (Procyon lotor). The effect of naturally occurring antibodies to
orthopoxviruses on successful V-RG vaccination in raccoons is the focus of this study.
Results: Overall, raccoons pre-immunized (n = 10) with a recombinant raccoonpox virus vaccine
(RCN-F1) responded to vaccination with V-RG with lower rabies virus neutralizing antibody (VNA)
titers than those which were not pre-immunized (n = 10) and some failed to seroconvert for rabies
VNA to detectable levels.
Conclusion: These results suggest that the success of some ORV campaigns may be hindered
where raccoonpox virus or possibly other orthopoxvirus antibodies are common in wildlife species
targeted for ORV. If these areas are identified, different vaccination strategies may be warranted.
Background
Oral rabies vaccination (ORV) programs for raccoons are
common in the eastern U.S. Raboral V-RG® (V-RG) is the
only licensed oral rabies vaccine for wildlife in the U.S.
This vaccine utilizes a live vaccinia virus (genus Orthopox-
virus) vector. Because oral rabies vaccination rates in rac-
coons (Procyon lotor) can be low in some areas [1], and
large expenses are involved in these types of campaigns
[2], it is important that all key factors that could affect vac-
cination rates be addressed.
Several naturally occurring orthopoxviruses can be found
throughout the world. For example, bank voles (Clethrion-
omys glareolus), woodmice (i.e., long-tailed field mice:
Apodemus sylvaticus) and Nowray lemmings (Lemmus lem-
mus) yielded evidence of orthopoxvirus antibodies in
Norway [3]. Similar associations were noted for select car-
nivore species in Fennoscandia [4] and red fox (Vulpes vul-
pes) in Germany [5]. In the U.S., endemic orthopoxvirus
examples include volepox virus found in California voles
(Microtus californicus; [6]), raccoonpox virus found in rac-
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coons [7,8], and skunkpox virus found in a striped skunk
(Mephitis mephitis; reviewed by [9]). Additional unrecog-
nized orthopoxviruses may exist in the U.S. For raccoon-
pox and skunkpox viruses, it is unknown whether the
species from which these viruses were obtained are the
true reservoir species (e.g., these viruses, like many other
orthopoxviruses, may be rodent-hosted), as little field
work has been conducted on these viruses since their dis-
covery.
It is unknown whether previous exposure to these North
American orthopoxviruses can inhibit the effectiveness of
V-RG vaccination in raccoons. However, it has been noted
that preexisting immunity to vaccinia virus may impede
the replication of vaccinia virus vectors and decrease the
response to the recombinant product [10]. The subject of
preexisting immunity has received some attention for
select vectored vaccines. For example, researchers [11]
indicated that mucosal vaccination overcame the barrier
of preexisting orthopoxvirus immunity of mice initially
immunized subcutaneously. Thirty-day old red fox (Vul-
pes vulpes) cubs with maternally derived antibodies from
V-RG serologically responded (i.e., rabies virus neutraliz-
ing antibody {VNA}) to oral vaccination with V-RG [12].
However, mice primed with avirulent ectromelia virus
survived a challenge with virulent ectromelia virus (genus
Orthopoxvirus) with no signs of morbidity [13]. In mice
pre-immunized with vaccinia virus and subsequently vac-
cinated with a recombinant vaccinia virus, antibody titers
against the recombinant gene product were lower and
lasted for a shorter duration [14]. In contrast, similar stud-
ies of adenoviruses suggested that the efficacy of oral vac-
cination is relatively unaltered by preexisting neutralizing
antibodies to the vaccine carrier [15]. For vaccinia virus,
the mechanism for such compromised immunity is
thought to be associated with long-term anti-vaccinia
immunological memory, which inhibits the replication/
priming of the second vaccinia recombinant virus such
that the amount of the non-vaccinia antigen produced by
the recombinant vector is no longer sufficient [14,16].
The effects of pre-existing immunity on vectored vaccines
have not been rigorously studied and different conclu-
sions have been drawn. Because this relationship has not
been thoroughly addressed for the oral vaccination of rac-
coons, the objective of this study was to determine
whether exposure to raccoonpox virus inhibits the suc-
cessful V-RG vaccination and development of rabies VNA
titers in raccoons in an experimental pen setting.
Results
Orthopoxvirus antibodies
Pre-treatment serology indicated that seven (four control
and three treatment) of twenty raccoons may have been
exposed to an orthopoxvirus prior to their capture, albeit
their antibody titers (1:5) were all at the threshold of
detection (geometric mean titer {GMT} < 1:5; treating all
< 1:5 titers as one significant digit less than the detection
limit). Assays on a second pre-treatment blood sample
were identical with one exception; the titer of one raccoon
increased from < 1:5 (e.g., below the detection limit) to
1:5 during its quarantine period prior to experimentation
(GMT < 1:5). Of these animals with pre-existing
orthopoxvirus antibodies at low titers, all yielded evi-
dence of rabies VNA following their second dose of V-RG.
Thirty days after a single dose (DPI) with the RCN-F1 vac-
cine (108 pfu), nine of 10 RCN-F1 treated raccoons (treat-
ment) had detectable antibodies to raccoonpox virus (i.e.,
≥1:5; range = < 1:5 – 1:20; GMT = 1:7). At that time, seven
of 10 control raccoons (those only vaccinated with V-RG)
were negative for antibodies reactive with this test; the
remaining three animals had pretreatment antibodies
(range < 1:5 – 1:5; GMT = < 1:5). Sixty-nine days following
the single RCN-F1 vaccination (36 days after the first V-RG
vaccination {107 pfu}), nine of 10 treatment animals had
raccoonpox virus antibodies (range < 1:5 – 1:20; GMT =
1:12), while three of 10 control animals had sera that was
reactive with this test (likely limited cross-reactivity of
antibodies to the vaccinia virus in V-RG in some animals;
range < 1:5 – 1:15; GMT = < 1:5). One animal was consist-
ent with its background levels, but the titer of the other
two animals increased. Ninety-seven DPI of the RCN-F1
vaccination, all treatment animals had positive raccoon-
pox virus antibody titers (range 1:5 – 1:15; GMT = 1:13),
while the sera of four of 10 control raccoons were positive
in this assay (range < 1:5 – 1:15; GMT = 1:6). The final
detection for raccoonpox virus antibodies was performed
on serum samples from 149 DPI of RCN-F1 vaccination
(31 days following the second dose of V-RG {108 pfu}).
Of the serum samples collected from that time point, all
treatment samples were raccoonpox virus antibody posi-
tive and had identical titers to those samples collected at
97 DPI (range 1:5 – 1:15; GMT = 1:13), while six of 10
control samples had antibodies reactive with the test
(range < 1:5 – 1:15; GMT = 1:7).
Rabies virus neutralizing antibodies
Seven of the raccoons that were used in this experiment
had evidence of pre-treatment/natural rabies VNA (four
control and three treatment raccoons). The positive anti-
body titers ranged from 0.20 – 0.80 IU/ml at that time.
The titers of six of the seven raccoons (three of four con-
trol animals and all treatment animals) decreased in a
subsequent serum sample. Prior to treatments being
employed, the geometric mean titers (treating all < 0.05
IU/ml titers as one significant digit less than the detection
limit) were 0.10 and 0.08 IU/ml for the control and treat-
ment groups, respectively (Figure 1A).BMC Immunology 2008, 9:57 http://www.biomedcentral.com/1471-2172/9/57
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Thirty-six days after the first V-RG vaccination (e.g., 107
pfu), seven of 20 raccoons yielded rabies VNA at detecta-
ble levels (≥ 0.05 IU/ml; range < 0.05 – 0.79 IU/ml; Figure
1B). Six of the seven were those with the pre-existing
rabies VNA mentioned above. One treatment raccoon had
detectable rabies VNA, albeit it was likely the pre-existing
antibodies that were detected, as its titer decreased follow-
ing vaccination. The GMTs were 0.14 and 0.06 IU/ml for
the control and treatment groups, respectively. Sixty-four
days after this vaccination, 10 of 20 raccoons yielded
rabies VNA at detectable levels (titer range < 0.05 – 1.6 IU/
ml; Figure 1C). Three of 10 treatment animals had detect-
able rabies VNA at that time point (range < 0.05 – 0.40 IU/
ml). The GMTs were 0.27 and 0.09 IU/ml for the control
and treatment groups, respectively.
Thirty-one days following the second V-RG vaccination
(108 pfu), 17 of 20 raccoons yielded evidence of rabies
VNA. The three that failed to seroconvert to detectable lev-
els were treatment animals. The rabies VNA titer range for
the control group was 0.20 to 67.0 IU/ml (7 of 10 animals
≥ 1.0 IU/ml), while the titer range for the treatment group
was < 0.05 – 2.6 IU/ml (3 of 10 animals ≥ 1.0 IU/ml). The
GMTs at this time point were 3.72 and 0.40 for the control
and treatment groups, respectively (Figure 1D). The ratio
of GMTs for rabies VNA from control to treatment rac-
coons was 9.3.
Histological findings
Following post-mortem examinations (day 252), gross
and histologic findings were consistent with previous
Graphical representation of rabies virus neutralizing antibodies (VNA) in raccoons during four time points including pre-exper- iment (A), 36 days post first V-RG vaccination (B), 64 days post first V-RG vaccination (C), and 31 days post second V-RG vac- cination Figure 1
Graphical representation of rabies virus neutralizing antibodies (VNA) in raccoons during four time points 
including pre-experiment (A), 36 days post first V-RG vaccination (B), 64 days post first V-RG vaccination (C), and 31 days 
post second V-RG vaccination. Treatment animals are those raccoons pre-vaccinated with RCN-F1 (a raccoonpox virus vec-
tored plague vaccine, see reference 25), while control animals are those which were not vaccinated with RCN-F1. The second 
V-RG vaccination was administered 85 days after the first vaccination (see discussion).BMC Immunology 2008, 9:57 http://www.biomedcentral.com/1471-2172/9/57
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reports of naturally occurring disease in wild raccoons.
The most commonly noted findings included chronic
interstitial nephritis, periportal hepatitis, myocardial sar-
cocysts and pneumoconiosis. Two raccoons had mild,
chronic inflammation in the choroid plexus and a single
animal had a hepatic adenoma. The lack of pathology that
can be definitively linked to the two orthopoxvirus-vec-
tored vaccines deployed further supports the safety of
both of these vaccines, even after three doses.
Discussion
Although the raccoons used in this study were captured in
Colorado, an area free of enzootic raccoon rabies, seven of
the raccoons that were used in this experiment had evi-
dence of pre-treatment rabies VNA. Thus, it is possible
that these animals were exposed to a different rabies virus
variant (e.g., bat), as this has been suggested as the cause
of rabies VNA in striped skunks (Mephitis mephitis) sam-
pled in areas thought to be free of skunk rabies in Alberta
[17]. It is also possible that they may have been previously
captured, vaccinated, and released, a common practice
among wildlife rehabilitators. Another, possibly the most
parsimonious, reason for the observation of the pretreat-
ment antibodies is non-specific virus inhibition. Of inter-
est, we and others have observed RFFIT positive sera
samples from raccoons collected in areas thought to be
free of raccoon rabies in multiple states. Future studies
should assess whether RFFIT positive samples observed in
wildlife sera obtained from areas free of terrestrial rabies
virus variants and ORV zones are actually positive due to
specific antibodies or other, non-specific factors. Notably,
Bahloul et al. presented data on presumably unvaccinated
dogs with fairly high background antibody rates and
observed distinct serological differences in dogs vacci-
nated in an experimental (pen) setting versus those in the
field [18]. As such, they suggested that a cutoff threshold
of 0.5 IU/ml should be interpreted cautiously and a
higher threshold might be more appropriate in the evalu-
ation of rabies immunity in natural settings to marginal-
ize various interfering factors [18].
Six of 10 control raccoons yielded evidence of antibodies
reactive with raccoonpox virus. However, some of the ani-
mals which failed to seroconvert for orthopoxvirus anti-
bodies (i.e., vaccinia virus antibodies reacting with
raccoonpox virus in the microneutralization test) to
detectable levels did seroconvert for rabies virus, occa-
sionally to high titers (e.g., > 10.0 IU/ml). Thus, only a
limited antibody response to vaccinia virus may occur in
raccoons when vaccinated with V-RG. However, consider-
ing that the majority of these animals did seroconvert, a
more probable explanation is that the assay we used may
only be marginally able to detect vaccinia virus antibod-
ies, as this assay utilizes raccoonpox virus for neutraliza-
tion.
Raccoons were dosed with V-RG twice because post-hoc
plaque assays indicated that our stock vaccine was approx-
imately one log lower than expected (e.g., 108 pfu/ml
rather than 109 pfu/ml) and initial serological results indi-
cated low vaccination rates in both groups of raccoons.
Nonetheless, the GMT differences of the treatment and
control groups in this study form a trend. Thirty-three
days after the initial dose of V-RG (107 pfu), the treatment
group yielded a GMT of 0.06 (CI = 0.0425 – 0.0795),
while the control group yielded a GMT of 0.14 IU/ml (CI
= 0.0751 – 0.2610; Figure 1B). Sixty-four days following
this initial vaccination, the GMTs increased to 0.09 (CI =
0.0509 – 0.15693) and 0.27 IU/ml (CI = 0.1213 –
0.6018) for the treatment and control groups, respectively
(Figure 1C). Thirty-one days after the second dose of V-RG
(108 pfu), the GMTs increased to 0.40 IU/ml (CI = 0.1635
– 0.9921) for the treatment group and 3.72 IU/ml (CI =
1.2682 – 10.9150) for the control group (Figure 1D).
Thus, the treatment we employed appears to have had an
effect on the V-RG induced seroconversions and the rabies
VNA titers produced in these raccoons. This is apparent
when one considers that some of the pre-immunized
(treatment) animals failed to seroconvert for rabies VNA
to detectable levels, even after two doses of V-RG, whereas
all control animals seroconverted. Nonetheless, the
majority of the treatment animals did seroconvert for
rabies VNA to detectable levels, albeit their responses were
variable among individuals. Our observation may be con-
sistent with others [14], who noted that the immunologi-
cal memory against vaccinia virus inhibited the
replication of a vaccinia recombinant during the second
infection, which also resulted in a suppressed response
against the recombinant gene product. Our vaccination
results are also confirmed by in vitro studies (JEO's Labo-
ratory) indicating that sera with anti-raccoonpox virus
antibodies can cause about a 1 log reduction in vaccinia
virus titers in the modified neutralization test we
employed. The cross-reactivity between raccoonpox virus
and other orthopoxviruses has been previously described
by others. Raccoonpox virus produces a hemagglutining
(HA) antigen that is inhibited by an antiserum to vaccinia
virus [7]. Alexander et al. reported that sera from raccoons
with antibody titers to raccoonpox virus partly cross-
reacted with vaccinia virus by the hemagglutining inhibi-
tion (HAI) assay [19]. Furthermore, in an experimental
study a raccoon inoculated with raccoonpox virus devel-
oped high HAI titers of 1:320 against raccoon poxvirus at
5 weeks post-inoculation [8]. The sera had also a HAI titer
of 1:40 against vaccinia virus [8].
Even though there was a distinct difference in the rabies
VNA GMTs between the treatment and control groups, we
did note a boosting effect in most animals following their
second V-RG vaccination. Thus, these data also suggest theBMC Immunology 2008, 9:57 http://www.biomedcentral.com/1471-2172/9/57
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possibility that a second high dose of V-RG might not be
inhibited by previous vaccination.
Although rabies VNA titers are not widely suitable as a
generic criterion for successful rabies vaccination in wild-
life [20], recent studies imply an increasing proportion of
raccoons are protected at higher titers [21]. For example,
in a study using three groups of raccoons considered to
have low-positive, medium-positive, and high-positive (>
0.45 IU/ml) rabies VNA titers, the highest level of post-
challenge survivorship (83%) was obtained in the group
considered high-positive; the other two groups were sig-
nificantly lower [21]. Of interest, low titers of antibodies
to raccoonpox virus may have completely inhibited V-RG
vaccination in three treatment animals and likely reduced
the rabies VNA titers in others. However, some treatment
animals yielded clear vaccination responses to V-RG.
Nonetheless, the low rabies VNA titers we observed in sev-
eral vaccinated treatment animals suggests that raccoons
with preexisting antibodies to raccoonpox virus will, on
average, have lower antibody titers following V-RG vacci-
nation. It should be noted, however, that rabies VNA are
only a part of the protective immune response produced
by V-RG, as other immunological processes may also be
important for the quality of the immune response.
Antibodies to naturally occurring orthopoxviruses in ORV
target species will likely be patchy in distribution. Old
World orthopoxviruses provide a well-studied example.
Boulanger and others [22] did not detect antibodies to
orthopoxviruses in wild red foxes in South Belgium (n =
72). A similar association was noted in France and various
parts of Belgium [23]. However, marginally high seroprev-
alence rates were found in red foxes in Germany (at least
16%) [5], Norway (11%), and Finland (50%; [4]). The
large-scale geographic variability of the aforementioned
results suggests that similar variability might be found in
other locations.
Conclusion
Orthopoxviruses endemic in the U.S. have received rela-
tively little attention in a field setting. However, antibody
prevalence to an orthopoxvirus (presumably raccoonpox
virus) in raccoons of nearly 24% has been reported with
positive hemagglutination inhibition antibody titers rang-
ing from 1:80 to 1:2560 [19]. Because it appears that at
least one naturally occurring orthopoxvirus can influence
successful oral vaccination or rabies VNA titers following
V-RG vaccinations, large-scale serosurveys are needed to
determine the extent and prevalence of naturally occur-
ring orthopoxviruses in the U.S and other areas where vac-
cinia-vectored wildlife vaccines are utilized for oral
vaccination. This may require novel assay development to
produce a test which can differentiate between vaccinia
and other orthopoxviruses. Thus, an approach similar to
published methods for West Nile virus and general flaviv-
iruses [24] may be warranted (e.g., a species independent
bELISA using multiple monoclonal antibodies). If evi-
dence of exposure to orthopoxviruses is found at high nat-
ural prevalences, different vaccination strategies may be
warranted in these areas for enhanced ORV success. These
results may help to explain the relatively low vaccination
rates of raccoons in some areas [1] if these endemic
orthopoxviruses are found there at high prevalence. How-
ever, vaccination rates of raccoons are undoubtedly influ-
enced by many other factors such as bait delivery, bait
density, and bait uptake.
Methods
Animal husbandry and handling
Twenty adult raccoons (mass range: 4.2 – 9.0 kg at cap-
ture) were live-trapped in Larimer County, Colorado. Fol-
lowing capture, raccoons were de-wormed, dusted for
ectoparasites, bled, and ear-tagged for individual identifi-
cation. The subject animals were bled on a second occa-
sion prior to experimentation and all were given a
minimum of a two week quarantine period prior to the
initiation of the experiment. Raccoons were individually
housed in 10 × 10 × 8' animal pens. Food and water were
replenished daily and general health checks were con-
ducted each day. Animal procedures were approved by the
National Wildlife Research Center's Animal Care and Use
Committee.
Each time raccoons were handled, they were anesthetized
with an intramuscular injection of a 5:1 mixture of keta-
mine/xylazine. For vaccination purposes, raccoons were
only lightly anesthetized to allow for swallow reflexes. On
day 0 of the experiment, 10 randomly chosen raccoons
were administered 108 pfu of a raccoonpox virus-vectored
plague vaccine (RCN-F1; [25]) per os to stimulate raccoon-
pox virus antibody production. To accomplish this, the
vaccine was slowly administered into the oral cavity of the
treatment animals with a 1 ml syringe. Following admin-
istration of the vaccine, the mouths of the animals were
held closed for approximately ten seconds. On day 30 of
the experiment, all raccoons were bled via the jugular
vein. On day 33, all raccoons were vaccinated with 107 pfu
of V-RG (titer range = 1 × 107 to 1.2 × 107; see discussion).
All raccoons were again bled on days 69 and 97. On day
118, all raccoons were vaccinated with a second dose of V-
RG (108 pfu; titer range = 1 × 108 to 1.5 × 108). All rac-
coons were bled again on days 139, 169, 200, 227, and
242 (Table 1). Blood samples were centrifuged to collect
serum samples and these samples were stored at -70°C in
cryovials prior to laboratory analyses. To save resources,
serological assays were not conducted for some of the
sampling time points.BMC Immunology 2008, 9:57 http://www.biomedcentral.com/1471-2172/9/57
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Serological and plaque assays
Rabies VNA titers were assessed using rapid fluorescent
focus inhibition tests (RFFIT) at a diagnostic laboratory.
In addition, a microneutralization assay was used to
assess raccoonpox virus antibody titers [25], although this
assay appears to have some cross-reactivity with other
orthopoxviruses (e.g., vaccinia). The raccoonpox virus
serological assays were conducted at JEO's lab (University
of Wisconsin). The detection threshold was 1:5 for the
microneutralization test and 0.05 IU/ml for the RFFIT.
Additionally, plaque assays were conducted to assess the
titer of the V-RG vaccine using slight modifications of pre-
viously outlined methods [26]. In brief, the vaccine innoc-
ulum was 10-fold serially diluted in BA-1. One hundred
microliters of each dilution was added in duplicate to
Vero cell monolayers in 6-well plates. After 1 hour of incu-
bation at 37°C, the cells were overlaid with 3 mL/well of
0.5% agarose in MEM medium supplemented with 5%
fetal bovine serum, 350 mg/L sodium bicarbonate, 29.2
mg/L L-glutamine, 100 units/mL penicillin, 100 mg/L
streptomycin, and 1 mg/L Fungizone, pH 7.6. After 48 hrs
of additional incubation, a second 3 mL 0.5% agarose
overlay containing 0.004% neutral red dye was added for
plaque visualization. Plaques were counted on days 3 and
4 following infection of the Vero cells. The limit of detec-
tion of this assay was 101.7 PFU/mL.
Post mortem examinations
On day 252, all raccoons were humanely euthanized and
post-mortem examinations were conducted at the Colo-
rado State University Veterinary Diagnostic Laboratory.
Although these necropsies were performed for other pur-
poses, some of the findings are mentioned in this paper
for post hoc safety evaluations of the two vaccines admin-
istered to raccoons.
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